Stay up to date with notifications from The IndependentNotifications can be managed in browser preferences.Jump to contentThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged inAllNewsSportCultureLifestyleA new dual-action drug, Ivonescimab, combined with chemotherapy, has shown promise in extending the lives of patients with advanced squamous non-small cell lung cancer. The investigational treatment works by disabling the 'off' switch used by tumours to evade the immune system and targeting a protein crucial for tumour growth. A trial involving 532 patients in China found that those receiving Ivonescimab and chemotherapy lived an average of 28 months, a 15 per cent increase compared to a control group. Experts have described these findings as a “promising step forward” for this hard-to-treat lung cancer, though further investigation is required. While side effects were more common with the new drug, the rate of patients discontinuing treatment due to side effects remained similar across both treatment groups. In fullNew dual-action drug a ‘promising step forward’ for patients with hard-to-treat lung cancerThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in
Newly developed drug helps extend the lives of lung cancer patients in trial
Stay up to date with notifications from The IndependentNotifications can be managed in browser preferences.Jump to contentThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged inAllNewsSportCultureLifestyleA new dual-action drug, Ivonescimab, combined with chemotherapy, has shown promise in extending the lives of patients with advanced squamous non-small cell lung cancer. The investigational treatment works by disabling the 'off' switch used by tumours to evade the immune system and targeting a protein crucial for tumour growth. A trial involving 532 patients in China found that those receiving Ivonescimab and chemotherapy lived an average of 28 months, a 15 per cent increase compared to a control group. Experts have described these findings as a “promising step forward” for this hard-to-treat lung cancer, though further investigation is required. While side effects were more common with the new drug, the rate of patients discontinuing treatment due to side effects remained similar across both treatment groups. In fullNew dual-action drug a ‘promising step forward’ for patients with hard-to-treat lung cancerThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in
